In vitro studies have demonstrated that breast cancer-associated fibroblasts can modulate tamoxifen resistance in breast cancers via activation of the PI3K/AKT and MAPK/ERK pathways and phosphorylation of estrogen receptor–α at serine 118 [122,123]. The gene discussed is AKT1; the disease is breast cancer.